Please login to the form below

Not currently logged in
Email:
Password:

Ruvise

This page shows the latest Ruvise news and features for those working in and with pharma, biotech and healthcare.

Novartis withdraws application for Ruvise approval in EU

Novartis withdraws application for Ruvise approval in EU

Had submitted imatinib mesylate for use in hypertension. The European Medicines Agency (EMA) has said that Novartis has withdrawn its marketing application for Ruvise in the treatment of high blood pressure. ... Ruvise (imatinib mesylate) is already

Latest news

More from news
Approximately 1 fully matching, plus 0 partially matching documents found.

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
COUCH Health

We are a patient engagement agency committed to making clinical study experiences human. By guiding organisations in making everything they...

Latest intelligence

Our Top 5 Pharma Picks From Cannes Lions
Here are five of Art's top five pharma and healthcare picks from Cannes Lions 2022....
The Evolving Role of the Sales Rep
The COVID-19 pandemic sparked an evolution in physician engagement. Jill Padgett, EdD, Head of Training, explores what this means for the sales force and shares her advice for succeeding in...
Measure your omnichannel maturity with our new tool
Try our Omnichannel Maturity Tool to gain tangible advice and an instant analysis of your omnichannel readiness....